Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 12
Submit an article Journal homepage
203
Views
31
CrossRef citations to date
0
Altmetric
Review

Targeting insulin-like growth factor-1 to treat Alzheimer's disease

Ignacio Torres-Aleman Cajal Institute, Laboratory of Neuroendocrinology, Avda. Dr Arce 37, 28002 Madrid, Spain +34 91 585 4723; +34 91 585 4754; [email protected]
Pages 1535-1542 | Published online: 18 Nov 2007

Bibliography

  • TERRY RD: Neuropathological changes in Alzheimer disease. Prog. Brain Res. (1994) 101:383-390.
  • GOLDE TE: Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest. (2003) 111:11-18.
  • ROBERSON ED, SCEARCE-LEVIE K, PALOP JJ et al.: Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science (2007) 316:750-754.
  • SELKOE DJ: Clearing the brain's amyloid cobwebs. Neuron (2001) 32:177-180.
  • BALLATORE C, LEE VMY, TROJANOWSKI JQ: Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. (2007) 8:663-672.
  • IQBAL K, GRUNDKE-IQBAL I: Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. Curr. Drug Targets (2004) 5:495-502.
  • HOYER S: The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural Transm. (2002) 109:991-1002.
  • FUJISAWA Y, SASAKI K, AKIYAMA K: Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol. Psychiatry (1991) 30:1219-1228.
  • BLUM-DEGEN D, FROLICH L, HOYER S et al.: Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J. Neural Transm. Suppl. (1995) 46:139-147.
  • JANSON J, LAEDTKE T, PARISI JE et al.: Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 53:474-481.
  • GASPARINI L, XU H: Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. (2003) 26:404-406.
  • CARRO E, TORRES-ALEMAN I: The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. (2004) 490:127-133.
  • FOSTER LA, AMES NK, EMERY RS: Food intake and serum insulin responses to intraventricular infusions of insulin and IGF-1. Physiol. Behav. (1991) 50:745-749.
  • DENLEY A, CARROLL JM, BRIERLEY GV et al.: Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol. Cell Biol. (2007) 27:3569-3577.
  • JONES JI, CLEMMONS DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. (1995) 16:3-34.
  • RUSSO VC, GLUCKMAN PD, FELDMAN EL et al.: The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. (2005) 26:916-943.
  • CLEMMONS DR: Clinical utility of measurements of insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. (2006) 2:436-446.
  • TREJO JL, CARRO E, LOPEZ-LOPEZ C et al.: Role of serum insulin-like growth factor I in mammalian brain aging. Growth Horm. IGF Res. (2004) 14(Suppl. A):39-43.
  • BONDY CA: Transient IGF-1 gene expression during the maturation of functionally related central projection neurons. J. Neurosci. (1991) 11:3442-3455.
  • BEILHARZ EJ, RUSSO VC, BUTLER G et al.: Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res. Mol. Brain Res. (1998) 59:119-134.
  • PARDRIDGE WM: Transport of insulin-related peptides and glucose across the blood–brain barrier. Ann. NY Acad. Sci. (1993) 692:126-137.
  • TORRES-ALEMAN I: Serum growth factors and neuroprotective surveillance. Mol. Neurobiol. (2000) 21:153-160.
  • NAKAHASHI T, FUJIMURA H, ALTAR CA et al.: Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. (2000) 470:113-117.
  • ROSENSTEIN JM, KRUM JM: New roles for VEGF in nervous tissue – beyond blood vessels. Exp. Neurol. (2004) 187:246-253.
  • ANSON RM, GUO Z, DE CABO R et al.: Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc. Natl. Acad. Sci. USA (2003) 100:6216-6220.
  • BARTKE A, CHANDRASHEKAR V, DOMINICI F et al.: Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology (2003) 4:1-8.
  • CASTRO-ALAMANCOS MA, TORRES-ALEMAN I: Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide. Proc. Natl. Acad. Sci. USA (1994) 91:10203-10207.
  • ALEMAN A, VERHAAR HJ, DE HAAN EH et al.: Insulin-like growth factor-I and cognitive function in healthy older men. J. Clin. Endocrinol. Metab. (1999) 84:471-475.
  • GARCIA J, AHMADI A, WONNACOTT A et al.: Association of insulin-like growth factor-1 receptor polymorphism in dementia. Dement. Geriatr. Cogn. Disord. (2006) 22:439-444.
  • MUSTAFA A, LANNFELT L, LILIUS L et al.: Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr. Cogn. Disord. (1999) 10:446-451.
  • THAM A, NORDBERG A, GRISSOM FE et al.: Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. (1993) 5:165-176.
  • WATANABE T, MIYAZAKI A, KATAGIRI T et al.: Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J. Am. Geriatr. Soc. (2005) 53:1748-1753.
  • MURIALDO G, BARRECA A, NOBILI F et al.: Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. J. Endocrinol. Invest. (2001) 24:139-146.
  • TEI E, YAMAMOTO H, WATANABE T et al.: Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. Growth Horm. IGF Res. (2007) [Epub ahead of print].
  • SVENSSON J, DIEZ M, ENGEL J et al.: Endocrine, liver-derived IGF-1 is of importance for spatial learning and memory in old mice. J. Endocrinol. (2006) 189:617-627.
  • TREJO JL, PIRIZ J, LLORENS-MARTIN MV et al.: Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol. Psychiatry (2007) [Epub ahead of print].
  • CARRO E, TORRES-ALEMAN I: Serum insulin-like growth factor I in brain function. Keio J. Med. (2006) 55:59-63.
  • DAVILA D, PIRIZ J, TREJO JL et al.: Insulin and insulin-like growth factor I signalling in neurons. Front. Biosci. (2007) 12:3194-3202.
  • HARRIDGE SD: Ageing and local growth factors in muscle. Scand. J. Med. Sci. Sports (2003) 13:34-39.
  • LIEBERMAN SA, MITCHELL AM, MARCUS R et al.: The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm. Metab. Res. (1994) 26:229-233.
  • NIBLOCK MM, BRUNSO-BECHTOLD JK, LYNCH CD et al.: Distribution and levels of insulin-like growth factor I mRNA across the life span in the Brown Norway × Fischer 344 rat brain. Brain Res. (1998) 804:79-86.
  • CARRO E, TREJO JL, GERBER A et al.: Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging (2006) 27:1250-1257.
  • YANKNER BA, DAWES LR, FISHER S et al.: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science (1989) 245:417-420.
  • CARRO E, TREJO JL, GOMEZ-ISLA T et al.: Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat. Med. (2002) 8:1390-1397.
  • ADLERZ L, HOLBACK S, MULTHAUP G et al.: IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J. Biol. Chem. (2007) 282:10203-10209.
  • CHENG CM, TSENG V, WANG J et al.: Tau is hyper-phosphorylated in the IGF1 null brain. Endocrinology (2005) 146:5086-5091.
  • FREUDE S, PLUM L, SCHNITKER J et al.: Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes (2005) 54:3343-3348.
  • SCHUBERT M, BRAZIL DP, BURKS DJ et al.: Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. (2003) 23:7084-7092.
  • AKIYAMA H, BARGER S, BARNUM S et al.: Inflammation and Alzheimer's disease. Neurobiol. Aging (2000) 21:383-421.
  • MIRANDA S, OPAZO C, LARRONDO LF et al.: The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Prog. Neurobiol. (2000) 62:633-648.
  • BEHL C, DAVIS JB, LESLEY R et al.: Hydrogen peroxide mediates amyloid β protein toxicity. Cell (1994) 77:817-827.
  • PRATICO D, TROJANOWSKI JQ: Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol. Aging (2000) 21:441-445.
  • FERNANDEZ AM, FERNANDEZ S, CARRERO P et al.: Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J. Neurosci. (2007) 27:8745-8756.
  • SCHABITZ WR, HOFFMANN TT, HEILAND S et al.: Delayed neuroprotective effect of insulin-like growth factor-i after experimental transient focal cerebral ischemia monitored with MRI. Stroke (2001) 32:1226-1233.
  • HOUSTIS N, ROSEN ED, LANDER ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature (2006) 440:944-948.
  • ZHONG J, LEE WH: Hydrogen peroxide attenuates insulin-like growth factor-1 neuroprotective effect, prevented by minocycline. Neurochem. Int. (2007) [Epub ahead of print].
  • VENTERS HD, TANG Q, LIU Q et al.: A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc. Natl. Acad. Sci. USA (1999) 96:9879-9884.
  • LADNER CJ, CZECH J, MAURICE J et al.: Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J. Neuropathol. Exp. Neurol. (1996) 55:924-931.
  • RUSSELL SJ, KAHN CR: Endocrine regulation of ageing. Nat. Rev. Mol. Cell Biol. (2007) 8:681-691.
  • AL-REGAIEY KA, MASTERNAK MM, BONKOWSKI M et al.: Long-lived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor i/insulin signaling and caloric restriction. Endocrinology (2005) 146:851-860.
  • HOLZENBERGER M, DUPONT J, DUCOS B et al.: IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature (2003) 421:182-187.
  • MOSTOSLAVSKY R, CHUA KF, LOMBARD DB et al.: Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 124:315-329.
  • FINKEL T, SERRANO M, BLASCO MA: The common biology of cancer and ageing. Nature (2007) 448:767-774.
  • TORRES-ALEMAN I: Role of insulin-like growth factors in neuronal plasticity and neuroprotection. Adv. Exp. Med. Biol. (2005) 567:243-258.
  • SELKOE DJ: Alzheimer's disease is a synaptic failure. Science (2002) 298:789-791.
  • KAKIZAWA S, YAMADA K, IINO M et al.: Effects of insulin-like growth factor I on climbing fibre synapse elimination during cerebellar development. Eur. J. Neurosci. (2003) 17:545-554.
  • NIETO-BONA MP, GARCIA-SEGURA LM, TORRES-ALEMAN I: Transynaptic modulation by insulin-like growth factor I of dendritic spines in Purkinje cells. Int. J. Dev. Neurosci. (1997) 15:749-754.
  • SHI L, LINVILLE MC, TUCKER EW et al.: Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb. Cortex. (2004) 15:571-577.
  • LEE CC, KUO YM, HUANG CC et al.: Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation. Neurobiol. Aging (2007) [Epub ahead of print].
  • GRANT WB, CAMPBELL A, ITZHAKI RF et al.: The significance of environmental factors in the etiology of Alzheimer's disease. J. Alzheimers Dis. (2002) 4:179-189.
  • POPE SK, SHUE VM, BECK C: Will a healthy lifestyle help prevent Alzheimer's disease? Annu. Rev. Public Health (2003) 24:111-132.
  • LOPEZ-LOPEZ C, LEROITH D, TORRES-ALEMAN I: Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc. Natl. Acad. Sci. USA (2004) 101:9833-9838.
  • LOPEZ-LOPEZ C, DIETRICH MO, METZGER F et al.: Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J. Neurosci. (2007) 27:824-831.
  • SONNTAG WE, LYNCH CD, COONEY PT et al.: Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology (1997) 138:3515-3520.
  • BOSSY-WETZEL E, SCHWARZENBACHER R, LIPTON SA: Molecular pathways to neurodegeneration. Nat. Med. (2004) 10(Suppl.):S2-S9.
  • GARCIA-GALLOWAY E, ARANGO C, PONS S et al.: Glutamate excitotoxicity attenuates insulin-like growth factor-i prosurvival signaling. Mol. Cell Neurosci. (2003) 24:1027-1037.
  • KOMATSU M, WAGURI S, CHIBA T et al.: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature (2006) 441:880-884.
  • AKI T, YAMAGUCHI K, FUJIMIYA T et al.: Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2. Oncogene (2003) 22:8529-8535.
  • YAMAMOTO A, CREMONA ML, ROTHMAN JE: Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. (2006) 172:719-731.
  • CATALDO AM, HAMILTON DJ, BARNETT JL et al.: Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J. Neurosci. (1996) 16:186-199.
  • YU WH, CUERVO AM, KUMAR A et al.: Macroautophagy – a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. (2005) 171:87-98.
  • TATTON WG, CHALMERS-REDMAN RM: Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann. Neurol. (1998) 44:S134-S141.
  • GUSTAFSSON H, ADAMSON L, HEDANDER J et al.: Insulin-like growth factor type 1 upregulates uncoupling protein 3. Biochem. Biophys. Res. Commun. (2001) 287:1105-1111.
  • HU P, HAN Z, COUVILLON AD et al.: Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J. Biol. Chem. (2004) 279:49420-49429.
  • FORMAN MS, LEE VM, TROJANOWSKI JQ: ‘Unfolding’ pathways in neurodegenerative disease. Trends Neurosci. (2003) 26:407-410.
  • CURTIS MA, FAULL RLM, ERIKSSON PS: The effect of neurodegenerative diseases on the subventricular zone. Nat. Rev. Neurosci. (2007) 8:712-723.
  • ANDERSON MF, ABERG MA, NILSSON M et al.: Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res. Dev. Brain Res. (2002) 134:115-122.
  • CRAFT S, PESKIND E, SCHWARTZ MW et al.: Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology (1998) 50:164-168.
  • FROLICH L, BLUM-DEGEN D, BERNSTEIN HG et al.: Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. (1998) 105:423-438.
  • GASPARINI L, NETZER WJ, GREENGARD P et al.: Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol. Sci. (2002) 23:288-293.
  • STEEN E, TERRY BM, RIVERA EJ et al.: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? J. Alzheimers Dis. (2005) 7:63-80.
  • TAUBES G: NEUROSCIENCE: Insulin insults may spur Alzheimer's disease. Science (2003) 301:40.
  • YOUDIM MB, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26:27-35.
  • BROWER V: IGF in the clinic. Nat. Biotechnol. (1998) 16:601-602.
  • CARRO E, SPUCH C, TREJO JL et al.: Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J. Neurosci. (2005) 25:10884-10893.
  • ALVAREZ A, CACABELOS R, SANPEDRO C et al.: Serum TNF-α levels are increased and correlate negatively with free IGF-1 in Alzheimer disease. Neurobiol. Aging (2006) 28:533-536.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.